Answers to Frequently Asked Questions About PAH
Pulmonary arterial hypertension (PAH) is high blood pressure in the arteries of the lungs (the pulmonary arteries). These arteries carry blood from the heart to the lungs, where the blood picks up oxygen before being pumped to the rest of your body.
Over time, the arteries in the lungs of a person with PAH become narrow. This narrowing increases the pressure within the arteries and decreases blood flow from the heart to the lungs. The increased pressure can also cause further injury to the arteries. The heart must then pump harder, causing the walls on the right side of the heart to thicken and weaken.
The most common symptoms of PAH are shortness of breath and feeling tired or weak. As PAH worsens, symptoms become more severe and interfere with daily activities.
Prostacyclin class therapy is an established treatment option for pulmonary arterial hypertension (PAH). It mimics some of the effects of prostacyclin, a substance naturally produced by the body to help keep blood vessels open and working properly.
You can learn more about pulmonary arterial hypertension (PAH) through the Pulmonary Hypertension Association (PHA) and the National Heart, Lung, and Blood Institute (NHLBI).
The PHA is a leading community-based organization for patients with PAH. Its mission is to find ways to prevent and cure PAH, while providing hope and practical services to the community of people who have PAH or have a loved one with this disorder. To learn more, visit www.PHAssociation.org.
The NHLBI is part of the National Institutes of Health (NIH), the agency responsible for conducting a majority of all federally funded medical research. The NHLBI website has easy-to-understand information about many diseases affecting the heart and lungs. Visit www.nhlbi.nih.gov, and search for “PAH.”